Book contents
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Chapter 1 Central Neuropathic Pain Signaling Pathways
- Chapter 2 Cannabinoids Pain Signaling Pathways
- Chapter 3 The Microbiome and Chronic Pain Syndromes
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Part VII Adjunctive Therapy
- Index
- References
Chapter 1 - Central Neuropathic Pain Signaling Pathways
from Part I - Introduction to Pain: Pain Signaling Pathways
Published online by Cambridge University Press: 01 December 2023
Book contents
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Chapter 1 Central Neuropathic Pain Signaling Pathways
- Chapter 2 Cannabinoids Pain Signaling Pathways
- Chapter 3 The Microbiome and Chronic Pain Syndromes
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Part VII Adjunctive Therapy
- Index
- References
Summary
Neuropathic pain (NP) is a common complication of spinal cord injury (SCI) that is difficult to treat. Chronic NP is associated with increased levels of inflammatory mediators and ion channel dysfunction, as well as nerve damage and nerve-glia crosstalk. Recent studies have made headway in identifying novel biomarkers, including microRNA and psycho-social attributes that can predict progress from SCI to chronic NP (CNP). Conventional medical treatment has limited success, but recent studies have identified new biomarkers and promising drugs, such as baclofen and ziconotide, that can provide pain relief. However, further studies are needed to determine the safety profile of these drugs. Nonmedical interventions, such as brain sensitization and biofeedback techniques, have also shown promise in managing CNP. A multidisciplinary approach, including psycho-social support, medical and nonmedical interventions, is necessary to effectively manage CNP in SCI patients.
- Type
- Chapter
- Information
- Cambridge Handbook of Pain Medicine , pp. 3 - 13Publisher: Cambridge University PressPrint publication year: 2023
References
Jensen, TS, Baron, R, Haanpää, M et al. A new definition of neuropathic pain. Pain. 2011; 152(10): 2204–2205. doi: 10.1016/j.pain.2011.06.017.CrossRefGoogle ScholarPubMed
Yekkirala, AS, Roberson, DP, Bean, BP, Woolf, CJ. Breaking barriers to novel analgesic drug development. Nature Reviews Drug Discovery. 2017; 16(8): 545–564. doi: 10.1038/nrd.2017.87.CrossRefGoogle ScholarPubMed
Staudt, MD, Clark, AJ, Gordon, AS et al. Long-term outcomes in the management of central neuropathic pain syndromes: A prospective observational cohort study. Can J Neurol Sci. 2018; 45(5): 545–552. doi: 10.1017/cjn.2018.55.CrossRefGoogle ScholarPubMed
Warner, FM, Cragg, JJ, Jutzeler, CR et al. Progression of neuropathic pain after acute spinal cord injury: A meta-analysis and framework for clinical trials. J Neurotrauma. 2019 15(1):40–48. doi: 10.1016/j.jpain.2013.09.008.Google Scholar
Finnerup, NB, Norrbrink, C, Trok, K et al. Phenotypes and predictors of pain following traumatic spinal cord injury: A prospective study. J Pain. 2014;15(1):40–48. doi: 10.1016/j.jpain.2013.09.008.CrossRefGoogle ScholarPubMed
Warner, FM, Cragg, JJ, Jutzeler, CR et al. The progression of neuropathic pain after acute spinal cord injury: A meta‐analysis and framework for clinical trials. J Neurotrauma. 2018;36(9):1461–1468.CrossRefGoogle ScholarPubMed
Gruener, H, Zeilig, G, Laufer, Y, Blumen, N, Defrin, R. Increased psychological distress among individuals with spinal cord injury is associated with central neuropathic pain rather than the injury characteristics. Spinal Cord. 2018;56(2):176–184. doi: 10.1038/s41393-017-0014-6.CrossRefGoogle Scholar
Vuckovic, A, Jajrees, M, Purcell, M, Berry, H, Fraser, M. Electroencephalographic predictors of neuropathic pain in subacute spinal cord injury. J Pain. 2018;19(11):1256.e1–1256.e17. doi: 10.1016/j.jpain.2018.04.011.CrossRefGoogle ScholarPubMed
Wang, Y, Ye, F, Huang, C et al. Bioinformatic analysis of potential biomarkers for spinal cord-injured patients with intractable neuropathic pain. Clin J Pain. 2018;34(9):825–830. doi: 10.1097/AJP.0000000000000608.CrossRefGoogle ScholarPubMed
Tang, Y, Liu, L, Xu, D et al. Interaction between astrocytic colony stimulating factor and its receptor on microglia mediates central sensitization and behavioral hypersensitivity in chronic post ischemic pain model. Brain Behav Immun. 2018;68:248–260.CrossRefGoogle ScholarPubMed
Chhaya, SJ, Quiros-Molina, D, Tamashiro-Orrego, AD, Houlé, JD, Detloff, MR. Exercise-induced changes to the macrophage response in the dorsal root ganglia prevent neuropathic pain after spinal cord injury. J Neurotrauma. 2019;36:877–890.CrossRefGoogle Scholar
Du, X-J, Chen, Y-X, Zheng, Z-C et al. Neural stem cell transplantation inhibits glial cell proliferation and P2X receptor-mediated neuropathic pain in spinal cord injury rats. Neural Regen Res. 2019;14(5):876–885.Google ScholarPubMed
Lee, SH, Shi, XQ, Fan, A, West, B, Zhang, J. Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain. Mol Pain. 2018;14:1–12.CrossRefGoogle ScholarPubMed
Kazuki, K, Toshiya, T, Yamanaka, H et al. Upregulation of calcium channel alpha-2-delta-1 subunit in dorsal horn contributes to spinal cord injury-induced tactile allodynia- ClinicalKey. Spinal J. 2018;18(6):1062–1069.Google Scholar
Sánchez-Brualla, I, Boulenguez, P, Brocard, C et al. Activation of 5-HT 2 A receptors restores KCC2 function and reduces neuropathic pain after spinal cord injury. Neuroscience. 2018;387:48–57.CrossRefGoogle ScholarPubMed
Li, T, Wan, Y, Sun, L et al. Inhibition of microRNA-15a/16 expression alleviates neuropathic pain development through upregulation of G protein-coupled receptor kinase 2. Biomol Ther. 2019;27(4):414–422.CrossRefGoogle ScholarPubMed
Yang, Z, Xu, J, Zhu, R, Liu, L. Down-regulation of miRNA-128 contributes to neuropathic pain following spinal cord injury via activation of P38. Med Sci Monit. 2017;23:405–411.CrossRefGoogle ScholarPubMed
Sanna, MD, Les, F, Lopez, V, Galeotti, N. Lavender (Lavandula angustifolia Mill.) essential oil alleviates neuropathic pain in mice with spared nerve injury. Front Pharmacol. 2019;10:472. doi: 10.3389/fphar.2019.00472. eCollection 2019.CrossRefGoogle ScholarPubMed
Warner, FM, Cragg, JJ, Jutzeler, CR et al. The progression of neuropathic pain after acute spinal cord injury: A meta‐analysis and framework for clinical trials. J Neurotrauma. 2018;36(9):1461–1468.CrossRefGoogle ScholarPubMed
Rosendahl, A, Krogh, S, Kasch, H. Pain assessment in hospitalized spinal cord injured patients–a controlled cross-sectional study. Sc and J Pain. 2018;19(2):299–307.CrossRefGoogle Scholar
Thibaut, A, Carvalho, S, Morse, L, Zafonte, R, Fregni, F. Delayed pain decrease following M1 tDCS in spinal cord injury: A randomized controlled clinical trial. Neurosci Lett. 2017;658:19–26.CrossRefGoogle ScholarPubMed
Widerström-Noga, E, Loeser, JD, Jensen, TS, Finnerup, NB. AAPT diagnostic criteria for central neuropathic pain. J Pain. 2017;18(12):1417–1426. doi: 10.1016/j.jpain.2017.06.003.CrossRefGoogle ScholarPubMed
Horan, NA, Pugh, TM. Intractable central pain in a patient with diffuse glioma. Am J Phys Med Rehabil. 2019;98:107–110.CrossRefGoogle Scholar
Levendoglu, F, Ogun, CO, Ozerbil, O, Ogun, TC, Ugurlu, H. Gabapentin is a first line drug for treatment of neuropathic pain in spinal cord injury. Spine. 2004;29:743–751.CrossRefGoogle ScholarPubMed
Siddall, PJ, Cousins, MJ, Otte, A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial. Neurol. 2006;67:1792–1800.CrossRefGoogle ScholarPubMed
Cardenas, DD, Nieshoff, EC, Suda, K et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurol. 2013;80:533–539.CrossRefGoogle ScholarPubMed
Vranken, JH, Dijkgraaf, MG, Kruis, MR et al. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150–157.CrossRefGoogle ScholarPubMed
Finnerup, NB, Sindrup, SH, Bach, FW, Johannesen, IL, Jensen, TS. Lamotrigine in spinal cord injury pain: A randomized controlled trial. Pain. 2002;96:375–383.CrossRefGoogle ScholarPubMed
Leijon, G, Boivie, J. Central post-stroke pain – A controlled trial of amitriptyline and carbamazepine. Pain. 1989;36:27–36.CrossRefGoogle Scholar
Rintala, DH, Holmes, SA, Courtade, D et al. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil. 2007;88:1547–1560.CrossRefGoogle ScholarPubMed
Vollmer, TL, Robinson, MJ, Risser, RC, Malcolm, SK. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract. 2014;14:732–744.CrossRefGoogle ScholarPubMed
Ellis, A, Grace, PM, Wieseler, J et al. Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav Immun. 2016;58:348–356.CrossRefGoogle Scholar
Svendsen, KB, Jensen, TS, Bach, FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253–260.CrossRefGoogle ScholarPubMed
Li, L, Han, Y, Li, T et al. The analgesic effect of intravenous methylprednisolone on acute neuropathic pain with allodynia due to central cord syndrome: A retrospective study. J Pain Res. 2018;11:1231–1238CrossRefGoogle ScholarPubMed
Kumru, H, Benito-Penalva, J, Kofler, M, Vidal, J. Analgesic effect of intrathecal baclofen bolus on neuropathic pian in spinal cord injury patients. Brain Res Bull. 2018;140:205–211.CrossRefGoogle Scholar
Brinzeu, A, Berthiller, J, Caillet, J-B, Staquet, H, Mertens, P. Ziconotide for spinal cord injury‐related pain. Eur J Pain. 2019;23(9):1688–1700.CrossRefGoogle ScholarPubMed
Galhardoni, R, da Silva, VA, Garcia-Larrea, L et al. Insular and anterior cingulate cortex deep stimulation for central neuropathic pain disassembling the percept of pain. Neurol. 2019;92(18):2165–2175.Google ScholarPubMed
Melzack, R. Pain and neuromatrix in the brain. J Dent Educ. 2001;65(12):1378–1382.CrossRefGoogle ScholarPubMed
Melzack, R, Wall, P. Pain mechanisms: a new theory. Surv Anesth. 1967;11:89–90.CrossRefGoogle Scholar
Melzack, R, Loeser, J. Phantom body pain in paraplegics: Evidence for a central “pattern generating mechanism” for pain. Pain. 1977;4:195–210.CrossRefGoogle Scholar
Karri, J, Li, S, Zhang, L et al. Neuropathic pain modulation after spinal cord injury by breathing-controlled electrical stimulation (BreEStim) is associated with restoration of autonomic dysfunction. J Pain Res. 2018;11:2331–2341.CrossRefGoogle ScholarPubMed
Boord, P, Siddall, P, Tran, Y et al. Electroencephalographic slowing and reduced reactivity in neuropathic pain following spinal cord injury. Spinal Cord. 2008;46:118–123.CrossRefGoogle ScholarPubMed
Wydenkeller, S, Maurizio, S, Dietz, V, Halder, P. Neuropathic pain in spinal cord injury: Significance of clinical and electrophysiological measures. Eur J Neurosci. 2009;30:91–99.CrossRefGoogle ScholarPubMed